Served More than 8 Million Testing in the First Semester of 2021, Prodia Recorded a 88.4% Net Revenue Growth to IDR 1.2 Trillion

JAKARTA, August 4, 2021 – PT Prodia Widyahusada Tbk (stock code: PRDA) managed to record a net revenue growth of 88.4% to Rp 1.2 trillion and an increase in net profit of more than 2.000% to Rp 301.02 billion compared to the same period in the previous year. In the First Semester of 2021, the Company has served more than 8 million testing which consists of genomic tests, routine tests, COVID-19 tests, and other medical tests.

The increase in net income in First Semester of 2021 was supported by revenue contributions from each customer segment. The individual customer segment and doctor's referrals contributed 68.19% to the Company's revenue. Meanwhile, the third party reference segment and corporate clients contributed 31.81% to the Company's revenue. Esoteric test revenue also grew by 214.9% to Rp 485.01 billion in line with the increasing number of requests for esoteric tests in the first semester of 2021 to around 1 million tests.

President Director of Prodia, Dewi Muliaty, said that "Prodia's achievements in the first six months of 2021 reflects our efforts to anticipate market uncertainty in our internal and to respond our customer needs. Currently, we have a strong financial position and continue to strive to generate solid revenues and profits so that we can continue to provide high returns for shareholders and sustainable added value for our stakeholders," Dewi explained in Jakarta (4/8).

Net profit margin and EBITDA margin increased to 24.3% and 35.9%, respectively. The company managed to book a current ratio of 663.1% and a fast ratio of 638.4%. This financial ratio also reflects Prodia's balance sheet which is also getting stronger.

The Company's total assets in the first semester of 2021 recorded an increase to Rp 2.4 trillion compared to the previous year. Current assets to Rp 1.49 trillion and non-current assets to Rp 898.79 billion. Meanwhile, total liabilities increased to Rp 462.94 billion. Meanwhile, short-term liabilities reached Rp 224.75 billion and long-term liabilities reached Rp 238.18 billion. Total Equity increased to Rp 1.93 trillion compared to 2020 which reached Rp 1.78 trillion.

In terms of cash flow, the Company managed to maintain net cash flow from operating activities in a surplus position in the first semester of 2021 to Rp 378.20 billion or an increase of 188.98% compared to the same period in 2020. The increase in net cash flow from operating activities This was mainly due to cash receipts from customers amounting to Rp 1.2 trillion. With a cash and cash equivalent position of Rp 473.29 billion, the Company has a solid financial position to support the Company's sustainable operations and business development.

In May 2021, Prodia won the Best Disclosure & Transparency award for the category of issuer with a middle market capitalization (Mid Cap) at the 12th IICD Corporate Governance Awards organized by the Indonesian Institute for Corporate Directorship (IICD) at the Financial Hall, Jakarta. IICD Corporate Governance Awards is an award ceremony for issuers that have implemented good corporate governance (GCG) practices in the previous year and are not related to serious cases that are contrary to GCG principles.

Furthermore, in order to support the government in increasing the coverage of COVID-19 vaccination in Indonesia, Prodia has prepared 56 clinical branches to perform independent vaccination services. "We are ready to partner with both private and state-owned enterprises for independent vaccination services at Prodia's health care facilities. Through the independent vaccination program, we hope to be able to contribute to efforts to accelerate the formation of herd immunity in Indonesia,” said Dewi.

Prodia is also one of the 742 laboratories affiliated with the Ministry of Health so that the results of the PCR and Prodia Antigen swab examinations can be used as flight requirements. Previously, Prodia had launched the Anti-SARS-CoV-2 Quantitative (Spike-RBD) examination to measure antibody titers against the COVID-19 virus and the Basic, Medium, Complete Pre-Vaccination panel for COVID-19, which functions to ensure the health condition of prospective vaccine recipients. COVID-19, especially those with comorbidities and the COVID-19 Recovery Basic, Recovery Medium and Recovery Complete Panels. With the examination panel, COVID-19 survivors can easily monitor their body's health condition after recovering from COVID-19.

*****

About PT Prodia Widyahusada Tbk

Prodia Clinical Laboratory was initially established in Solo on 7 May 1973 by a group of idealist pharmacists. From the very first, Andi Wijaya, along with the other founders have been committed to present the best test results with wholehearted services.

As the market leader, since 2012 Prodia has been the only laboratory and clinic in Indonesia accredited by the College of American Pathologists (CAP). It implies that Prodia' s test results are equal in quality to those obtained from other international laboratories.

On 7 December 2016, the Indonesia Stock Exchange officially listed the initial public offering of Prodia as the 15th issuer in 2016, with the ticker symbol 'PRDA'. In that corporate action, Prodia offered 187.5 million shares. Accordingly, the fund raised from the Company' s initial public offering (IPO) was Rp1.22 trillion.

Currently, Prodia has had the service network that incorporates 263 outlets, across 127 cities and 34 provinces in Indonesia, Prodia Health Care (PHC) - a personalized medicine-based wellness clinic - and specialty clinics, including Prodia Children' s Health Centre (PCHC), Prodia Women' s Health Centre (PWHC), and Prodia Senior Health Centre (PSHC).

Prodia has launched Kontak Prodia 1500-830 and the online-based virtual personal assistant Tanya Prodia (TANIA). TANIA can be accessed by anyone, especially Prodia customers directly anytime and anywhere online including via LINE: @prodia.id, Telegram: @prodia.id, Facebook Messenger: @prodia.id and Prodia Website: www.prodia.co.id.

For more information, please visit www.prodia.co.id or contact: